These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20820186)

  • 1. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
    Hawksworth D; Ravindranath L; Chen Y; Furusato B; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):311-5. PubMed ID: 20820186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
    Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
    Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression.
    Yang G; Timme TL; Frolov A; Wheeler TM; Thompson TC
    Cancer; 2005 Mar; 103(6):1186-94. PubMed ID: 15712208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
    Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
    Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
    Mark HF; Samy M; Santoro K; Mark S; Feldman D
    Exp Mol Pathol; 2000 Feb; 68(1):65-9. PubMed ID: 10640455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
    Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
    Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility.
    Solé X; Hernández P; de Heredia ML; Armengol L; Rodríguez-Santiago B; Gómez L; Maxwell CA; Aguiló F; Condom E; Abril J; Pérez-Jurado L; Estivill X; Nunes V; Capellá G; Gruber SB; Moreno V; Pujana MA
    BMC Genomics; 2008 Jan; 9():12. PubMed ID: 18190704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
    Jenkins RB; Qian J; Lieber MM; Bostwick DG
    Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics.
    Udager AM; DeMarzo AM; Shi Y; Hicks JL; Cao X; Siddiqui J; Jiang H; Chinnaiyan AM; Mehra R
    Prostate; 2016 Jun; 76(9):845-53. PubMed ID: 27159573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
    Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.
    Sterbis JR; Gao C; Furusato B; Chen Y; Shaheduzzaman S; Ravindranath L; Osborn DJ; Rosner IL; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S; Cullen J; Petrovics G
    Clin Cancer Res; 2008 Feb; 14(3):758-63. PubMed ID: 18245536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The expression of c-myc protein in uterine cervical cancer: a possible prognostic indicator].
    Wu HJ
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Jul; 48(7):515-21. PubMed ID: 8754393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1.
    Dvorácková J; Uvírová M
    Neoplasma; 2007; 54(2):149-54. PubMed ID: 17319789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
    Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
    Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
    Watson SK; Woolcock BW; Fee JN; Bainbridge TC; Webber D; Kinahan TJ; Lam WL; Vielkind JR
    Prostate; 2009 Jun; 69(9):961-75. PubMed ID: 19267368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer progression, metastasis, and gene expression in transgenic mice.
    Perez-Stable C; Altman NH; Mehta PP; Deftos LJ; Roos BA
    Cancer Res; 1997 Mar; 57(5):900-6. PubMed ID: 9041192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance.
    Schleger C; Verbeke C; Hildenbrand R; Zentgraf H; Bleyl U
    Mod Pathol; 2002 Apr; 15(4):462-9. PubMed ID: 11950922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
    J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.